Abiopharma

(30% Negative) Adicet Bio, Inc. (ACET) Announces Delay in data Trials for October from our prula-cel P Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington’s Disease

Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference

FibroBiologics CEO Issues Letter to Shareholders

GeneDx Announces GenomeDx Prenatal™, Expanding Industry-Leading Genomic Diagnosis Into Prenatal Care

EUDA Health Holdings Ltd (EUDAW) Files Form 6-K

Palisade Bio Announces Strategic Equity Investment from the Crohns & Colitis Foundations IBD Ventures Program to Advance PALI-2108

Evaxion Biotech A/S (EVAX) Files Form 6-K

Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108

SeaStar Medical Announces 2026 Milestones

ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus

Purple Biotech Ltd. (PPBT) Files Form 6-K

(99% Neutral) 4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 2025 Financial Results

Natera - Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer